Literature DB >> 24329526

The TCR γδ repertoire and relative gene expression characteristics of T-ALL cases with biclonal malignant Vδ1 and Vδ2 T cells.

Haitao Zheng1, Xu Wang, Yu Ma, Bing Xu, Shaohua Chen, Lijian Yang, Xiuli Wu, Grzegorz K Przybylski, Suming Huang, Tiezhen Ye, Yangqiu Li.   

Abstract

Despite significant improvement in our understanding of T-cell acute lymphoblastic leukemia (T-ALL) biology and pathogenesis, many questions remain unanswered. In previous studies, we found a T-ALL case with two malignant T-cell clones with Vδ1Dδ2Dδ3Jδ1 and Vδ2Dδ3Jδ2 rearrangements. In this study, we further characterized T-ALL cases with two malignant clones containing Vδ1Dδ3Jδ1 and Vδ2Dδ1Jδ1 rearrangements using fine-tiling array comparative genomic hybridization, ligation-mediated polymerase chain reaction (LM-PCR), sequencing, and reverse transcription polymerase chain reaction (RT-PCR) analysis. We further analyzed the distribution and clonality of the T-cell receptor (TCR) Vγ and Vδ subfamily T cells in the two T-ALL cases by RT-PCR and GeneScan. Monoclonal Vδ1 and Vδ2 subfamilies were confirmed in both samples, the Vδ3 through Vδ7 subfamilies could not be detected in the T-ALL samples, whereas the oligoclonal Vδ8 subfamily could be identified. Based on the clinical finding that both of the T-ALL cases with two malignant T-cell clones had a poor outcome, we attempted to compare the expression pattern of genes related to T-cell activation and proliferation between cases with the malignant Vδ1 and Vδ2 T-cell clones and T-ALL cases with a mono-malignant Vα T-cell clone. We selected two T-ALL cases with VαJα rearrangements and analyzed the expression level of Notch1, TAL1, and the CARMA-BCL10-MALT-A20-NF-κB pathway genes by real-time PCR. A20 had significantly higher expression in the biclonal compared with the monoclonal T-ALL group (p=0.0354), and there was a trend toward higher expression for the other genes in the biclonal group with the exception of TAL1, although the differences were not statistically significant. In conclusion, we identified two T-ALL cases with biclonal malignant T-cell clones and described the characteristics of the biclonal T-ALL subtype and its gene expression pattern. Thus, our findings may improve the understanding of biclonal T-ALL.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24329526      PMCID: PMC3880916          DOI: 10.1089/dna.2013.2199

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  47 in total

1.  Clonal evolution of adult T-cell leukemia/lymphoma takes place in the lymph nodes.

Authors:  Akira Umino; Masao Nakagawa; Atae Utsunomiya; Kunihiro Tsukasaki; Naoya Taira; Naoyuki Katayama; Masao Seto
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

2.  Comparison of the distribution and clonal expansion features of the T-cell γδ repertoire in myelodysplastic syndrome-RAEB and RAEB with progression to AML.

Authors:  Suxia Geng; Jianyu Weng; Xin Du; Peilong Lai; Xin Huang; Shaohua Chen; Lijian Yang; Yangqiu Li
Journal:  DNA Cell Biol       Date:  2012-08-08       Impact factor: 3.311

3.  Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study.

Authors:  Yu Wang; Dai-Hong Liu; Zhi-Ping Fan; Jing Sun; Xiao-Jin Wu; Xiao Ma; Lan-Ping Xu; Kai-Yan Liu; Qi-Fa Liu; De-Pei Wu; Xiao-Jun Huang
Journal:  Clin Transplant       Date:  2012-04-19       Impact factor: 2.863

Review 4.  Notch in T-ALL: new players in a complex disease.

Authors:  Ute Koch; Freddy Radtke
Journal:  Trends Immunol       Date:  2011-07-19       Impact factor: 16.687

5.  TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.

Authors:  Keiichiro Honma; Shinobu Tsuzuki; Masao Nakagawa; Hiroyuki Tagawa; Shigeo Nakamura; Yasuo Morishima; Masao Seto
Journal:  Blood       Date:  2009-07-16       Impact factor: 22.113

6.  Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL1 locus: a Pediatric Oncology Group study.

Authors:  R O Bash; W M Crist; J J Shuster; M P Link; M Amylon; J Pullen; A J Carroll; G R Buchanan; R G Smith; R Baer
Journal:  Blood       Date:  1993-04-15       Impact factor: 22.113

Review 7.  T-cell acute lymphoblastic leukemia occurring in a patient with acute promyelocytic leukemia.

Authors:  V Liso; G Specchia; A Pannunzio; A Mestice; G Palumbo; A Biondi
Journal:  Haematologica       Date:  1998-05       Impact factor: 9.941

8.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.

Authors:  Adolfo A Ferrando; Donna S Neuberg; Jane Staunton; Mignon L Loh; Christine Huard; Susana C Raimondi; Fred G Behm; Ching Hon Pui; James R Downing; D Gary Gilliland; Eric S Lander; Todd R Golub; A Thomas Look
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

9.  Aberrant TAL1 activation is mediated by an interchromosomal interaction in human T-cell acute lymphoblastic leukemia.

Authors:  B Patel; Y Kang; K Cui; M Litt; M S J Riberio; C Deng; T Salz; S Casada; X Fu; Y Qiu; K Zhao; S Huang
Journal:  Leukemia       Date:  2013-05-23       Impact factor: 11.528

10.  Pre-natal, clonal origin of acute lymphoblastic leukaemia in triplets.

Authors:  Jan Zuna; Katerina Muzikova; Anthony M Ford; Ana Teresa Maia; Ondrej Krejci; Katerina Tousovska; Irina Oravkinova; Mel Greaves; Jan Trka
Journal:  Leuk Lymphoma       Date:  2003-12
View more
  8 in total

1.  Treatment response and outcome of children with T-cell acute lymphoblastic leukemia expressing the gamma-delta T-cell receptor.

Authors:  Ching-Hon Pui; Deqing Pei; Cheng Cheng; Suzanne L Tomchuck; Scarlett N Evans; Hiroto Inaba; Sima Jeha; Susana C Raimondi; John K Choi; Paul G Thomas; Mari Hashitate Dallas
Journal:  Oncoimmunology       Date:  2019-05-17       Impact factor: 8.110

2.  Arsenic induced complete remission in a refractory T-ALL patient with a distinct T-cell clonal evolution without molecular complete remission: A case report.

Authors:  Suijing Wu; Ling Xu; Xin Huang; Suxia Geng; Yan Xu; Shaohua Chen; Lijian Yang; Xiuli Wu; Janyu Weng; Xin DU; Yangqiu Li
Journal:  Oncol Lett       Date:  2016-05-05       Impact factor: 2.967

3.  Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia.

Authors:  Yu Ma; Ziwei Liao; Yi Xu; Ziyun Zhong; Xu Wang; Fan Zhang; Shaohua Chen; Lijian Yang; Gengxin Luo; Xin Huang; Suming Huang; Xiuli Wu; Yangqiu Li
Journal:  Eur J Med Res       Date:  2014-11-11       Impact factor: 2.175

4.  Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI.

Authors:  Ling Xu; Jianyu Weng; Xin Huang; Chengwu Zeng; Shaohua Chen; Suxia Geng; Lijian Yang; Suijing Wu; Suming Huang; Xin Du; Yangqiu Li
Journal:  Oncotarget       Date:  2016-07-12

5.  γδ T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Discussion of Two Pediatric Cases and Its Distinction from Other Mature γδ T-Cell Malignancies.

Authors:  Eric X Wei; Vasiliki Leventaki; John K Choi; Susana C Raimondi; Elizabeth M Azzato; Sheila A Shurtleff; Menchu G Ong; Diana M Veillon; James D Cotelingam; Rodney E Shackelford
Journal:  Case Rep Hematol       Date:  2017-09-24

Review 6.  γδ T Cells: The Ideal Tool for Cancer Immunotherapy.

Authors:  Mahboubeh Yazdanifar; Giulia Barbarito; Alice Bertaina; Irma Airoldi
Journal:  Cells       Date:  2020-05-24       Impact factor: 6.600

Review 7.  γδ T Cells for Leukemia Immunotherapy: New and Expanding Trends.

Authors:  Mateus de Souza Barros; Nilberto Dias de Araújo; Fábio Magalhães-Gama; Thaís Lohana Pereira Ribeiro; Fabíola Silva Alves Hanna; Andréa Monteiro Tarragô; Adriana Malheiro; Allyson Guimarães Costa
Journal:  Front Immunol       Date:  2021-09-22       Impact factor: 7.561

8.  Analysis of the expression of PHTF1 and related genes in acute lymphoblastic leukemia.

Authors:  Xin Huang; Suxia Geng; Jianyu Weng; Zesheng Lu; Lingji Zeng; Minming Li; Chengxin Deng; Xiuli Wu; Yangqiu Li; Xin Du
Journal:  Cancer Cell Int       Date:  2015-10-05       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.